FDA Approves Expanded Indication for Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

On March 16, 2023, The U.S Food and Drug Administration approved a supplementary New Drug Application for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom lutetium-177 (177Lu) PSMA-directed therapy is indicated.

For more information read the Telix Pharmaceuticals announcement.

Posted 3/29/2023